Guardant Health Inc
GH - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.26B
Close$
Earnings Call Q2 2026
July 30, 2026 - AI Summary
Strong Q2 growth across all segments (good):
- Revenue: $335M, +44% YoY (broad-based: Oncology, Biopharma & Data, Screening).
- Oncology: $219M, +38% YoY; ~104k tests, +63% YoY.
- Guardant360 Liquid: >30% YoY growth (Smart app adoption).
- Guardant360 Tissue: accelerated; second-fastest growing product.
- Reveal (MRD/therapy monitoring): >100% YoY volume growth; strong ramp and therapy monitoring contributing meaningfully.
- Biopharma & Data: $61M, +9% YoY (record quarter); growing companion diagnostic franchise (28 CDx approvals, 4 added in 1H 2026).
- Screening (Shield): $53M, +~3.3x YoY (from ~$15M); ~66k tests (from ~16k).
Major product/regulatory catalysts (surprising + opportunity):
- FDA approval of Guardant360 Liquid CDx (May 2026): integrates genomic + epigenomic (methylation/epigenomic content); major milestone; phased rollout already started.
- Guardant360 Liquid CDx ADLT expected in H1 2027 (enables Medicare Advantage/commercial repricing).
- FDA approval for higher-throughput, lower-COGS Shield workflow (June; live in production August): expected to reduce Shield cost/test (step-down initially) and improve lab scalability.
- Shield commercial acceptance: included in American Cancer Society CRC guidelines; UnitedHealth Group coverage decision (effective Aug 1) for ages 45+ (primary CRC screening option).
2026 guidance raised (good) with clear demand + cost trajectory:
- Full-year revenue guidance: raised to $1.34B–$1.36B (+36% to +38% YoY).
- Oncology: now expects ~30% revenue growth and ~50% volume growth (portfolio strength across Liquid/Tissue/Reveal despite tougher comps).
- Screening (Shield): raised to $218M–$230M and 270k–285k Shield tests (confidence increased after ACS inclusion + UnitedHealth coverage starting Aug 1).
- Gross margin (non-GAAP): outlook maintained at 64%–65% (lower testing costs partially offset by mix; Shield + Reveal scaling).
- OpEx: $1.08B–$1.1B (+20% to +22% YoY), reflecting expanded Screening commercialization investment.
- Free cash flow: expects burn $195M–$205M (about $10M worse vs prior, driven by additional CapEx to expand Shield lab capacity); committed to cash flow breakeven by end of 2027.
Exclusive for Stockcircle Pro members
Sign up
$-135.41
188.3% downside
Current Fair Value
188.3% downsideOvervalued by 188.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $20.26 Billion |
|---|---|
| Enterprise Value | $20.92 Billion |
| Earnings per Share | $-3.32 |
| Beta | 1.58 |
| Outstanding Shares | 132,074,000 |
Return
| Return on Equity | 203.46% |
|---|---|
| Return on Assets | -23.71% |
| Return on Invested Capital | -28.82% |
Valuation & Multiples
| P/E Ratio | -51.23 |
|---|---|
| PEG | -252.83 |
| Price to Sales | 19.18 |
| Price to Book Ratio | -76.72 |
| Enterprise Value to Revenue | 17.69 |
| Enterprise Value to EBIT | -46.14 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -7.69 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.75
Consensus analyst estimateRevenue Estimate
$350.72 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 18, 2027
EPS Estimate
$-0.73
Consensus analyst estimateRevenue Estimate
$369.29 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 100.98% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 94,800▼ 89.64% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.88%▼ 100.48% |
|---|---|
| Total Invested | $438.05M▼ 97.83% |
| Investors Holding | 177▼ 450.00% |